These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34418415)

  • 21. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung Ultrasound to Diagnose Pulmonary Congestion Among Patients on Hemodialysis: Comparison of Full Versus Abbreviated Scanning Protocols.
    Reisinger N; Lohani S; Hagemeier J; Panebianco N; Baston C
    Am J Kidney Dis; 2022 Feb; 79(2):193-201.e1. PubMed ID: 34090905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK): A study protocol for a randomized controlled trial.
    Haroon SW; Tai BC; Ling LH; Teo L; Davenport A; Schurgers L; Teo BW; Khatri P; Ong CC; Low S; Yeo XE; Tan JN; Subramanian S; Chua HR; Tan SY; Wong WK; Lau TW
    Medicine (Baltimore); 2020 Sep; 99(36):e21906. PubMed ID: 32899022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis.
    Memmos E; Sarafidis P; Pateinakis P; Tsiantoulas A; Faitatzidou D; Giamalis P; Vasilikos V; Papagianni A
    BMC Nephrol; 2019 Jun; 20(1):217. PubMed ID: 31185930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excess volume removal following lung ultrasound evaluation decreases central blood pressure and pulse wave velocity in hemodialysis patients: a LUST sub-study.
    Loutradis C; Papagianni A; Ekart R; Theodorakopoulou M; Minopoulou I; Pagourelias E; Douma S; Karagiannis A; Mallamaci F; Zoccali C; London G; Sarafidis PA
    J Nephrol; 2020 Dec; 33(6):1289-1300. PubMed ID: 32447618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary congestion predicts cardiac events and mortality in ESRD.
    Zoccali C; Torino C; Tripepi R; Tripepi G; D'Arrigo G; Postorino M; Gargani L; Sicari R; Picano E; Mallamaci F;
    J Am Soc Nephrol; 2013 Mar; 24(4):639-46. PubMed ID: 23449536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the CHA2DS2-VASc Score in Predicting Mortality and Adverse Cardiovascular Outcomes of Patients on Hemodialysis.
    Schamroth Pravda M; Cohen Hagai K; Topaz G; Schamroth Pravda N; Makhoul N; Shuvy M; Benchetrit S; Assali A; Pereg D
    Am J Nephrol; 2020; 51(8):635-640. PubMed ID: 32702703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
    Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
    J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemodialysis Self-management Intervention Randomized Trial (HED-SMART): A Practical Low-Intensity Intervention to Improve Adherence and Clinical Markers in Patients Receiving Hemodialysis.
    Griva K; Nandakumar M; Ng JH; Lam KFY; McBain H; Newman SP
    Am J Kidney Dis; 2018 Mar; 71(3):371-381. PubMed ID: 29198641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
    Strippoli GF;
    Trials; 2010 Jun; 11():70. PubMed ID: 20534124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.
    Tepel M; van der Giet M; Statz M; Jankowski J; Zidek W
    Circulation; 2003 Feb; 107(7):992-5. PubMed ID: 12600912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of heart failure in hemodialysis-dependent end-stage renal disease patients with myocardial fibrosis quantification by extracellular volume on cardiac magnetic resonance imaging.
    Xu HY; Yang ZG; Zhang Y; Peng WL; Xia CC; Li ZL; He Y; Xu R; Rao L; Peng Y; Li YM; Gao HL; Guo YK
    BMC Cardiovasc Disord; 2020 Jan; 20(1):12. PubMed ID: 31924159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current opinion in quantitative lung ultrasound for the nephrologist.
    Reisinger N; Koratala A
    Curr Opin Nephrol Hypertens; 2023 Nov; 32(6):509-514. PubMed ID: 37753644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes.
    Grooteman MP; van den Dorpel MA; Bots ML; Penne EL; van der Weerd NC; Mazairac AH; den Hoedt CH; van der Tweel I; Lévesque R; Nubé MJ; ter Wee PM; Blankestijn PJ;
    J Am Soc Nephrol; 2012 Jun; 23(6):1087-96. PubMed ID: 22539829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventive dental care reduces risk of cardiovascular disease and pneumonia in hemodialysis population: a nationwide claims database analysis.
    Mikami R; Mizutani K; Ishimaru M; Gohda T; Iwata T; Aida J
    Sci Rep; 2024 May; 14(1):12372. PubMed ID: 38811608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
    O'Connor CM; Whellan DJ; Lee KL; Keteyian SJ; Cooper LS; Ellis SJ; Leifer ES; Kraus WE; Kitzman DW; Blumenthal JA; Rendall DS; Miller NH; Fleg JL; Schulman KA; McKelvie RS; Zannad F; Piña IL;
    JAMA; 2009 Apr; 301(14):1439-50. PubMed ID: 19351941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of pulmonary congestion by chest ultrasound in dialysis patients.
    Mallamaci F; Benedetto FA; Tripepi R; Rastelli S; Castellino P; Tripepi G; Picano E; Zoccali C
    JACC Cardiovasc Imaging; 2010 Jun; 3(6):586-94. PubMed ID: 20541714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ambulatory Pulse Wave Velocity Is a Stronger Predictor of Cardiovascular Events and All-Cause Mortality Than Office and Ambulatory Blood Pressure in Hemodialysis Patients.
    Sarafidis PA; Loutradis C; Karpetas A; Tzanis G; Piperidou A; Koutroumpas G; Raptis V; Syrgkanis C; Liakopoulos V; Efstratiadis G; London G; Zoccali C
    Hypertension; 2017 Jul; 70(1):148-157. PubMed ID: 28483919
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.